+117.5%
EOG vs MRNA
-27.3%
+144.7%
-33.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.6% | -2.2% | +1.6% | -0.6% |
| 7D | -6.1% | -12.7% | +6.6% | -6.1% |
| 30D | -5.9% | -20.7% | +14.8% | -5.8% |
| 3M | -1.7% | +46.3% | -48.0% | -2.1% |
| 6M | +6.4% | +305.2% | -298.8% | +3.3% |
| YTD | +46.0% | +561.2% | -515.2% | +38.6% |
| 1Y | +44.6% | +772.1% | -727.5% | +35.6% |
| 3Y | +32.0% | +147.0% | -114.9% | +26.7% |
| All | +117.5% | -27.3% | +144.7% | +100.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling